<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362021">
  <stage>Registered</stage>
  <submitdate>31/01/2012</submitdate>
  <approvaldate>2/02/2012</approvaldate>
  <actrnumber>ACTRN12612000149864</actrnumber>
  <trial_identification>
    <studytitle>An open label clinical trial of an orally-dosed herbal formulation Zinova (Registered Trademark) for the prevention of dysmenorrhoea (menstrual pain).</studytitle>
    <scientifictitle>An open label clinical trial of an orally-dosed herbal formulation Zinova (Registered Trademark) for the prevention of dysmenorrhoea (menstrual pain) in females with a normal menstrual cycle (28-32 days).</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Dysmenorrhoea</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Menstruation and menopause</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The investigational product is Zinova (Registered Trademark), a provisionally patented two piece capsule-form medication containing three chemically defined herbal extracts Terminalia chebula (300 mg), Curcumin BetaSorb (Registered Trademark) (100mg) and Zingiber officinale (80mg). The participants take 4 capsules/day (2 in the morning and 2 in the evening) for 3 months, commencing on day 1 of follicular phase of the menstrual cycle.</interventions>
    <comparator>none</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Assess the effectiveness of the treatment in reducing menstrual pain during the menstrual cycle, assessed using visual analogue scale (VAS).</outcome>
      <timepoint>Baseline Menstruation (Daily during menstruating using a patient diary)
Month 1, 2 and 3 (Daily during menstruation using a patient diary)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the effectiveness of the treatment in reducing analgesic use during the menstrual cycle using a patient diary detailing medication type/dosage/time.</outcome>
      <timepoint>Baseline Menstruation (Daily during menstruating using a patient diary)
Month 1, 2 and 3 (Daily during menstruation using a patient diary)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Female
Aged 18 to 45 
Normal Menstrual Cycle 28-32 days for at least 6 months</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Irregular menstrual cycles
Peri-menopausal
Menopausal
Chronic health problems- diabetes, heart disease, renal/liver disease
Reproductive health problems - eg PCOS, endometriosis, 
Depression
Pregnant
Lactating
Attempting pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>1. Patients complete an on-Line screening questionnaire
2. Patients are booked in to clinic
3. Patients attend clinic for a pre-trial interview
4. Patients are enrolled into the study
5. Patients provided numbered bottles in order of enrolment
6. No concealment</concealment>
    <sequence>n/a</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>n/a</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/04/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Applied Science and Nutrition Pty. Ltd.</primarysponsorname>
    <primarysponsoraddress>P.O. Box 68
New Farm 4005
Brisbane QLD</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Trilogie Products Pty. Ltd.</fundingname>
      <fundingaddress>PO Box 417
Mona Vale
NSW, 1660</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a single-site, open-label  short-term clinical trial with baseline data collection.

Approximately 20 female participants aged between 18 and 45 years will be recruited from the CROs participant database and public media. Following initial screening via telephone, potential participants will attend the clinic for an information session and will be requested to provide their consent for inclusion in the trial. Consenting potential participants will undergo a medical assessment including lifestyle, current medications, physical examination, medical history, and menstrual history; this data will be used for the comprehensive screening and to provide contextual data for the study.


The primary outcome measure is the pain VAS  rating scales. The secondary outcome measure is analgesic use. 

The expected duration of the trial is five consecutive menses (approximately five months) for each participant. Baseline data will be collected during the first 2 menstrual cycles prior to intervention and for 3 months while on treatment.</summary>
    <trialwebsite>n/a</trialwebsite>
    <publication>n/a</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Australian College of Natural Medicine</ethicname>
      <ethicaddress>362 Water Street
Fortitude Valley 4006
Brisbane, QLD.</ethicaddress>
      <ethicapprovaldate>2/03/2009</ethicapprovaldate>
      <hrec>HREC-020</hrec>
      <ethicsubmitdate>8/07/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Amanda Rao</name>
      <address>188 James Street
New Farm 4005
Brisbane, QLD</address>
      <phone>+ 61 414 488559</phone>
      <fax />
      <email>amanda@asnresearch.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Amanda Rao</name>
      <address>188 James Street
New Farm 4005
Brisbane, QLD</address>
      <phone>+ 61 414 488559</phone>
      <fax>n/a</fax>
      <email>amanda@asnresearch.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>ELizabeth Steels</name>
      <address>188 James Street
New Farm 4005
Brisbane, QLD</address>
      <phone>+61 431 003 929</phone>
      <fax>n/a</fax>
      <email>beth@asnresearch.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>